Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VNDA with free AI briefings, catalyst countdowns, and dilution alerts.

VNDA · Vanda Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$140.5M Cash on Hand
14.2mo Cash Runway
13.2% Short Interest
$11.5 Analyst Target (5)
Follow VNDA by email Get an email when VNDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VNDA, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2026-12-12 Quimilza generalized pustular psoriasis (GPP) BLA 67%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What VNDA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Iloperidone
FDA approved May 2009 · Fanapt
Schizophrenia Phase 4 · NCT05648591 Recruiting
Tradipitant (VLY-686)
FDA approved Dec 2025 · Nereus
Motion Sickness Phase 3 · NCT06138613 Active not recruiting
Tasimelteon
FDA approved Jan 2014 · Hetlioz
Autism Spectrum Disorder Phase 3 · NCT05361707 Unknown
Ponesimod
FDA approved Mar 2021 · Ponvory
Ulcerative Colitis (UC) Phase 3 · NCT07686081 Recruiting
Milsaperidone
FDA approved Feb 2026 · Bysanti
Major Depressive Disorder (MDD) Phase 3 · NCT06830044 Recruiting
Teverelix Generalized Pustular Psoriasis Phase 3 · NCT05352893 Completed
VQW-765 Social Anxiety Disorder (SAD) Phase 3 · NCT07221578 Active not recruiting
Tasimelteon Oral Suspension Insomnia Disorder Phase 3 · NCT06953869 Recruiting
Open Label Tradipitant Idiopathic Gastroparesis Phase 3 · NCT04028492 Completed
Imsidolimab Generalized Pustular Psoriasis Phase 3 · NCT05366855 Terminated
Trichostatin A Onychomycosis of Toenail Phase 2 · NCT07065773 Active not recruiting
VCA-894A Charcot Marie Tooth Disease (CMT) Phase 1/2 · NCT07223632 Active not recruiting
VSJ-110 Dry Eye Phase 2 · NCT07179055 Recruiting
VHX-896 Healthy Phase 1 · NCT06803290 Completed
Active Control Healthy Volunteers Phase 1 · NCT06323655 Completed

Also used in these trials (approved or third-party drugs, not VNDA's own candidates): Ziprasidone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VNDA holds $140.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.8M/quarter from operations, an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VNDA files for a raise →

👥 Who Owns VNDA

Insiders 9.2% Other 5%+ holders 7% Institutions (225 holders) 83.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 8,466,183 14.00% 2026-09-30
Millennium Management LLC 5%+ holder (13G) 4,260,038 7.04% 2026-09-30
BlackRock Portfolio Management LLC Institution (13G, 5%+) 3,587,013 5.93% 2026-09-30
Renaissance Technologies, LLC Institution (13F) 3,308,441 5.47% 2026-09-30
State Street Corporation Institution (13F) 3,010,531 4.98% 2026-09-30
Mihael Hristos Polymeropoulos
President and CEO, Director
Insider 2,704,496 4.47% 2026-03-02
Vanguard Capital Management LLC Institution (13F) 2,537,629 4.20% 2026-09-30
AIGH Capital Management LLC Institution (13F) 2,250,000 3.72% 2026-09-30
AQR Capital Management, LLC Institution (13F) 2,096,939 3.47% 2026-09-30
Marshall Wace LLP Institution (13F) 2,082,839 3.44% 2026-09-30
Acadian Asset Management. LLC Institution (13F) 1,779,748 2.94% 2026-09-30
Dimensional Fund Advisors LP Institution (13F) 1,748,916 2.89% 2026-09-30

Share count 60,469,687 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-05
filed 2026-11-05
Duncan Charles Cliff
Purchase (P) 5,803 $3.80 108,701
2026-11-04
filed 2026-11-05
Duncan Charles Cliff
Purchase (P) 3,447 $3.82 102,898
2026-11-03
filed 2026-11-05
Duncan Charles Cliff
Purchase (P) 750 $3.80 99,451
2026-06-04
filed 2026-06-08
Chrousos Phaedra
Award (A) 41,600 – 164,950
2026-06-04
filed 2026-06-08
DUGAN RICHARD W
Award (A) 41,600 – 219,054

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-02-21 — NDA -27.4% +41.5% +54.7%
2025-12-30 NEREUS™ (tradipitant) NDA +35.9% -2.4% +12.9%

Browse all historical PDUFA outcomes →

Get the full VNDA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VNDA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.